Haemonetics
HAE
241 hedge funds and large institutions have $3.39B invested in Haemonetics in 2022 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 82 increasing their positions, 91 reducing their positions, and 27 closing their positions.
22% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 27
4% more capital invested
Capital invested by funds: $3.26B → $3.39B (+$137M)
0.46% more ownership
Funds ownership: 100.9% → 101.35% (+0.46%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less funds holding
Funds holding: 242 → 241 (-1)
10% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 91
16% less call options, than puts
Call options by funds: $11.3M | Put options by funds: $13.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$49.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$37.8M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$32.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$24.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCOV
London Company of Virginia
Richmond,
Virginia
|
-$47.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$31.2M |
| 3 |
RRAM
River Road Asset Management
Louisville,
Kentucky
|
-$28M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$26.7M |
| 5 |
BlackRock
New York
|
-$21.7M |
HAE Hedge Fund Activity: Q2 2022 in Review
241 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2022, worth a combined $3.39B — up 4.2% from $3.26B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new HAE positions and 27 closed out — a net gain of 6 holders — while 82 added to existing stakes and 91 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $49.1M. The largest seller was London Company of Virginia, cutting an estimated $47.8M.
- 241 institutional investors held Haemonetics (HAE) as of Q2 2022, down from 242 in Q1 2022.
- Funds reported $3.39B of Haemonetics stock for Q2 2022, up 4.2% quarter-over-quarter.
- 33 funds opened new Haemonetics positions in Q2 2022 and 27 closed out, a net change of +6 holders.
- The largest Haemonetics buyer in Q2 2022 was Capital Research Global Investors, an estimated $49.1M added.
- The largest Haemonetics seller in Q2 2022 was London Company of Virginia, an estimated $47.8M sold.
Based on aggregated 13F filings for Q2 2022.